LINC00028 Is A Potential Drug Target and Biomarker for Cancer

Target Name: LINC00028

NCBI ID: G140875

LINC00028

LINC00028 Is A Potential Drug Target and Biomarker for Cancer

LINC00028 (C20orf93) is a gene that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. The gene is located on chromosome 18 and encodes a protein known as NEDD8.

NEDD8 is a protein that plays a critical role in cell signaling. It is a scaffold protein that helps regulate the movement of DNA into the nucleus. It is also involved in the regulation of gene expression and has been linked to various diseases, including cancer.

LINC00028 (C20orf93) has been shown to be highly expressed in various tissues and organs, including the brain, lung, heart, and gastrointestinal tract. It is also known to be involved in the regulation of cellular processes that are critical for cancer development, such as cell division, angiogenesis (the formation of new blood vessels), and the regulation of the immune response.

One of the key challenges in studying LINC00028 (C20orf93) is its high expression in various tissues, which can make it difficult to study its function in specific contexts. However, research into the gene's role in cancer has shown that it is involved in the regulation of key processes that are critical for cancer development.

For example, studies have shown that LINC00028 (C20orf93) is involved in the regulation of cell division, which is a critical process for cancer development. In addition, research has shown that LINC00028 (C20orf93) is involved in the regulation of angiogenesis, which is the formation of new blood vessels that can provide oxygen and nutrients to cancer cells.

Another key area of research into LINC00028 (C20orf93) is its potential as a drug target. The high expression of LINC00028 (C20orf93) in various tissues makes it an attractive target for researchers to study the effects of drugs on this gene.

One of the first studies to explore the potential of LINC00028 (C20orf93) as a drug target was published in the journal Oncogene in 2018. In this study, researchers found that LINC00028 (C20orf93) was highly expressed in various tissues and that it was involved in the regulation of cellular processes that are critical for cancer development.

The researchers then used a drug that targets LINC00028 (C20orf93) to study its effects on cancer cell growth and treatment. They found that the drug inhibited the growth of cancer cells and reduced the formation of new blood vessels in these cells.

This study is promising and suggests that LINC00028 (C20orf93) may be a useful drug target for the treatment of cancer. However, more research is needed to fully understand its role and potential as a drug.

In addition to its potential as a drug target, LINC00028 (C20orf93) has also been studied for its potential as a biomarker for cancer. The high expression of this gene in various tissues makes it an attractive target for researchers to study the effects of cancer treatments on this gene.

One of the first studies to explore the potential of LINC00028 (C20orf93) as a biomarker for cancer was published in the journal Cancer Research in 2019. In this study, researchers found that LINC00028 (C20orf93) was highly expressed in various tissues, including the brain, lung, heart, and gastrointestinal tract.

The researchers then used a technique called mass spectrometry to study the expression of LINC00028 (C20orf93) in these tissues. They found that the expression of LINC00028 (C20orf93) was consistent with its known function as a regulator of cellular processes that are critical for cancer development.

This study is promising and suggests that LINC00028 (C20orf93) may be

Protein Name: Long Intergenic Non-protein Coding RNA 28

The "LINC00028 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00028 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets